Assessing Patient Eligibility for CAR-T Therapy

Opinion
Video

This segment explores factors influencing patient candidacy for CAR-T therapy, including age, fitness, and relapse specifics, and evaluates key findings from the KarMMa trials to compare ide-cel with other second-line treatment options for multiple myeloma.

Video content above is prompted by the following:

  • What factors make Rosie a strong candidate for CAR-T therapy?
  • How do considerations like her age, overall fitness, and specifics of her relapse shape your decision?
  • Are there other treatment paths you would explore for this patient?
  • Let’s examine the data backing the use of ide-cel in this context:
  • Which major findings from the KarMMa and KarMMa-3 trials are most relevant to your decision-making?
  • How do these outcomes compare with other second-line options available for multiple myeloma?

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
1 expert is featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
5 experts are featured in this series
5 experts are featured in this series
2 experts in this video
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
2 experts in this video
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Related Content